D
David Siegel
Researcher at Novartis
Publications - 2
Citations - 322
David Siegel is an academic researcher from Novartis. The author has contributed to research in topics: Bortezomib & Panobinostat. The author has an hindex of 2, co-authored 2 publications receiving 314 citations. Previous affiliations of David Siegel include University of Medicine and Dentistry of New Jersey.
Papers
More filters
Journal ArticleDOI
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Paul G. Richardson,Constantine S. Mitsiades,Kathleen Colson,Eileen Reilly,Laura McBride,Judy Chiao,L. Sun,Justin L. Ricker,Syed Rizvi,Carol Oerth,Barbara Atkins,Ivy Fearen,Kenneth C. Anderson,David Siegel +13 more
TL;DR: Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease, demonstrating modest single-agent activity in relapsed/refractory multiple myeloma, and maximum tolerated doses (MTDs) were determined.
Journal ArticleDOI
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
Jesús F. San-Miguel,Paul G. Richardson,Andreas Günther,Orhan Sezer,David Siegel,Joan Bladé,Richard Leblanc,Heather J. Sutherland,Monika Sopala,Kaushal Mishra,Song Mu,Priscille M. Bourquelot,Maria-Victoria Mateos,Kenneth C. Anderson +13 more
TL;DR: The maximum-tolerated dose (MTD) of panobinostat plus bortezomib was determined and demonstrated activity in patients with relapsed or relapsed/refractory multiple myeloma, including bortzomib-refractor patients.